ECSP056018A - Triazoles sustituidos con biarilo como bloqueantes del canal de sodio - Google Patents

Triazoles sustituidos con biarilo como bloqueantes del canal de sodio

Info

Publication number
ECSP056018A
ECSP056018A EC2005006018A ECSP056018A ECSP056018A EC SP056018 A ECSP056018 A EC SP056018A EC 2005006018 A EC2005006018 A EC 2005006018A EC SP056018 A ECSP056018 A EC SP056018A EC SP056018 A ECSP056018 A EC SP056018A
Authority
EC
Ecuador
Prior art keywords
compounds
pain
alone
effective amount
combination
Prior art date
Application number
EC2005006018A
Other languages
English (en)
Inventor
Prasun K Chakravarty
Michael H Fisher
Brenda Palucki
Min K Park
William H Parsons
Bishan Zhou
James P Carey
Douglas E Frantz
Michael H Kress
Damian Weaver
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ECSP056018A publication Critical patent/ECSP056018A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de triazol sustituidos con biarilo representados por la fórmula I, II o III o sales farmacéuticamente aceptables de los mismos, y un proceso para preparar dichos compuestos y sales de los mismos. Las composiciones farmacéuticas comprenden una cantidad eficaz de los presentes compuestos, solos o en combinación con uno o más compuestos terapéuticamente activos y un vehículo farmacéuticamente aceptable. Los procedimientos de tratamiento de afecciones asociadas a o causadas por la actividad de canal de sodio, incluyendo por ejemplo, dolor agudo, dolor crónico, dolor visceral, dolor inflamatorio, dolor neuropático, epilepsia, síndrome del intestino irritable, depresión, ansiedad, esclerosis múltiple y trastorno bipolar, comprenden administrar una cantidad eficaz de los presentes compuestos, solos o en combinación con uno o más compuestos terapéuticamente activos. Un procedimiento de administración de anestesia local comprende administrar una cantidad eficaz de un compuesto de la presente invención, solo o en combinación con uno o más compuestos terapéuticamente activos, y un vehículo farmacéuticamente activo.
EC2005006018A 2003-03-18 2005-09-14 Triazoles sustituidos con biarilo como bloqueantes del canal de sodio ECSP056018A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45595203P 2003-03-18 2003-03-18

Publications (1)

Publication Number Publication Date
ECSP056018A true ECSP056018A (es) 2006-01-27

Family

ID=33030073

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005006018A ECSP056018A (es) 2003-03-18 2005-09-14 Triazoles sustituidos con biarilo como bloqueantes del canal de sodio

Country Status (34)

Country Link
US (2) US7326726B2 (es)
EP (1) EP1606269B1 (es)
JP (1) JP4482554B2 (es)
KR (1) KR100737721B1 (es)
CN (2) CN1788002A (es)
AR (1) AR044503A1 (es)
AT (1) ATE412639T1 (es)
AU (1) AU2004221885C1 (es)
BR (1) BRPI0408407A (es)
CA (1) CA2519252C (es)
CL (1) CL2004000551A1 (es)
CY (1) CY1108720T1 (es)
DE (1) DE602004017438D1 (es)
DK (1) DK1606269T3 (es)
EC (1) ECSP056018A (es)
EG (1) EG25994A (es)
ES (1) ES2314387T3 (es)
HR (1) HRP20050816A2 (es)
IS (1) IS8001A (es)
JO (1) JO2480B1 (es)
MA (1) MA27665A1 (es)
MX (1) MXPA05009847A (es)
MY (1) MY142651A (es)
NO (1) NO20054775L (es)
NZ (1) NZ542205A (es)
PE (1) PE20041066A1 (es)
PL (1) PL1606269T3 (es)
PT (1) PT1606269E (es)
RU (1) RU2356897C2 (es)
SI (1) SI1606269T1 (es)
TW (1) TWI337605B (es)
UA (1) UA81660C2 (es)
WO (2) WO2004083189A1 (es)
ZA (1) ZA200506906B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101413143B (zh) 2002-12-19 2013-09-18 斯克里普斯研究学院 稳定甲状腺素运载蛋白和抑制甲状腺素运载蛋白错折叠的组合物和方法
AR044503A1 (es) * 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
RU2372339C2 (ru) * 2003-11-10 2009-11-10 Мерк Энд Ко., Инк. Замещенные триазолы в качестве блокаторов натриевых каналов
AU2005245470A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP1943216B1 (en) 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
JP2010516734A (ja) * 2007-01-24 2010-05-20 グラクソ グループ リミテッド 3,5−ジアミノ−6−(2,3−ジクロロフェニル)−1,2,4−トリアジンまたはr(−)−2,4−ジアミノ−5−(2,3−ジクロロフェニル)−6−フルオロメチルピリミジンを含む医薬組成物
NZ579403A (en) * 2007-02-08 2012-03-30 Synta Pharmaceuticals Corp Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
ME02847B (me) 2009-07-27 2018-01-20 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
ES2648820T3 (es) 2011-05-10 2018-01-08 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de los canales de sodio
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
WO2013038351A1 (en) 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
ES2694001T3 (es) 2013-03-15 2018-12-17 Bristol-Myers Squibb Company Moduladores de LXR
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
JP2020536870A (ja) 2017-10-05 2020-12-17 バイオジェン インコーポレイテッド アルファカルボキサミドピロリジン誘導体の調製方法
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
US20210002232A1 (en) * 2018-03-09 2021-01-07 Pi Industries Ltd. Heterocyclic compounds as fungicides
CN108794413A (zh) * 2018-06-25 2018-11-13 青岛科技大学 一种1,2,4-三氮唑-3-甲酰胺的合成方法
CN108863965A (zh) * 2018-06-25 2018-11-23 青岛科技大学 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875782A (en) * 1907-04-29 1908-01-07 Walter H Cook Fast-nut.
TW226993B (es) * 1992-05-29 1994-07-21 Kumiai Chemical Industry Co
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
JP3682075B2 (ja) * 1993-04-16 2005-08-10 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫、殺ダニ剤
MY129541A (en) * 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
IT1292091B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
UA72244C2 (en) * 1999-03-26 2005-02-15 Aryl-substituted pyrazols, imidazols, oxazols, thiazols, pyrrols and their use
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
CA2445568A1 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
MXPA05000279A (es) * 2002-07-09 2005-03-31 Squibb Bristol Myers Co Derivados heterociclicos sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo.
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
AR044503A1 (es) * 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
RU2372339C2 (ru) * 2003-11-10 2009-11-10 Мерк Энд Ко., Инк. Замещенные триазолы в качестве блокаторов натриевых каналов

Also Published As

Publication number Publication date
US7572822B2 (en) 2009-08-11
IS8001A (is) 2005-08-29
PT1606269E (pt) 2008-12-16
PL1606269T3 (pl) 2009-04-30
WO2004083189A1 (en) 2004-09-30
AR044503A1 (es) 2005-09-14
MXPA05009847A (es) 2005-12-05
KR20050109583A (ko) 2005-11-21
NO20054775L (no) 2005-12-16
UA81660C2 (ru) 2008-01-25
ES2314387T3 (es) 2009-03-16
TW200505876A (en) 2005-02-16
ZA200506906B (en) 2007-02-28
TWI337605B (en) 2011-02-21
US7326726B2 (en) 2008-02-05
CL2004000551A1 (es) 2005-01-21
RU2356897C2 (ru) 2009-05-27
AU2004221885A1 (en) 2004-09-30
AU2004221885B2 (en) 2010-04-22
MY142651A (en) 2010-12-15
EP1606269B1 (en) 2008-10-29
WO2004083190A1 (en) 2004-09-30
NO20054775D0 (no) 2005-10-17
DE602004017438D1 (de) 2008-12-11
ATE412639T1 (de) 2008-11-15
PE20041066A1 (es) 2005-01-22
CN101289428A (zh) 2008-10-22
EP1606269A1 (en) 2005-12-21
JP2006520782A (ja) 2006-09-14
US20080171777A1 (en) 2008-07-17
DK1606269T3 (da) 2009-02-09
RU2005132168A (ru) 2006-04-27
JP4482554B2 (ja) 2010-06-16
EG25994A (en) 2012-11-28
HRP20050816A2 (hr) 2006-04-30
CA2519252C (en) 2008-11-18
CN1788002A (zh) 2006-06-14
SI1606269T1 (sl) 2009-02-28
US20050119261A1 (en) 2005-06-02
NZ542205A (en) 2008-11-28
KR100737721B1 (ko) 2007-07-11
CA2519252A1 (en) 2004-09-30
MA27665A1 (fr) 2005-12-01
BRPI0408407A (pt) 2006-03-21
JO2480B1 (en) 2009-01-20
AU2004221885C1 (en) 2010-09-23
CY1108720T1 (el) 2013-09-04

Similar Documents

Publication Publication Date Title
ECSP056018A (es) Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
HRP20251504T1 (hr) N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kao modulatori natrijevih kanala
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
WO2004084824A3 (en) Biaryl substituted 6-membered heterocyles as sodium channel blockers
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
DK0766672T3 (da) Arylsulfonamido-substituerede hydroxamsyrer som matrixmetallopreteinase-inhibitorer
NO20062676L (no) Substituerte triazoler som natriumkanalblokkere
AR084473A1 (es) Composiciones farmaceuticas de (r) 1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropanecarboxamida
RU2010126056A (ru) Органические соединения
WO2008064107A3 (en) 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods
CO6270360A2 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
RU2011127079A (ru) Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с
EA023500B1 (ru) Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты
WO2007145922A3 (en) Benzazepinones as sodium channel blockers
JOP20220227A1 (ar) مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة
WO2008157404A3 (en) Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
PH12022550790A1 (en) Oral complement factor d inhibitors
TW200502222A (en) Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
DOP2004000850A (es) Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
RU2013113301A (ru) Замещенные 2-оксо- и 2-тиоксо-дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
MX2024002892A (es) Azalidos inmunomoduladores.
JPWO2020079165A5 (es)
RU2008129623A (ru) Ингибиторы ccr9 активности
RU2011147382A (ru) Соединения, создающие физиологический эффект
UY28340A1 (es) Profármaco inhibidor de beta-lactamasa